- Home
- ADI vs AZN Comparison
ADI vs AZN Comparison
Compare ADI & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADI | AZN |
|---|---|---|
| Founded | 1965 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.3B | 316.4B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADI | AZN |
|---|---|---|
| Price | $416.16 | $179.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 1 |
| Target Price | ★ $385.45 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 1.8M |
| Earning Date | 05-20-2026 | 04-29-2026 |
| Dividend Yield | 1.13% | ★ 1.73% |
| EPS Growth | ★ 39.02 | N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | ★ $6,200,942,000.00 | N/A |
| Revenue This Year | $28.41 | $10.34 |
| Revenue Next Year | $10.25 | $6.43 |
| P/E Ratio | $100.78 | ★ $31.91 |
| Revenue Growth | ★ 21.41 | N/A |
| 52 Week Low | $218.38 | $68.62 |
| 52 Week High | $439.70 | $212.71 |
Technical Indicators
Market Signals| Indicator | ADI | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 43.54 |
| Support Level | $381.22 | $174.60 |
| Resistance Level | $437.71 | $191.50 |
| Average True Range (ATR) | 17.58 | 3.10 |
| MACD | -2.55 | -0.00 |
| Stochastic Oscillator | 57.36 | 33.11 |
Price Performance
Historical ComparisonAbout ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.